ASIC1 and pulmonary arterial hypertension: We further demonstrate that deletion of SM-Asic1a in mice with established pulmonary hypertension effectively reversed increases in RVSP, RV hypertrophy, and vascular remodeling, signifying ASIC1 as a potential therapeutic target for pulmonary hypertension.